ArriVent BioPharma 株価情報 (NASDAQ: AVBP)

最新ニュース ArriVent BioPharma (NASDAQ:AVBP) 株価情報

ArriVent BioPharma

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma Inc

B of A Securities analyst David Barden maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Buy and raises the price target from $240 to $255.

News

Price Target

Analyst Ratings

TMUS

B of A Securities Maintains Buy on T-Mobile US, Raises Price Target to $255

The U.S. telecom sector has delivered a robust performance over the past year, outpacing broader market gains. The S&amp;P Telecom Select Industry Index surged around 37% over the past year, significantly outperforming the <a href="https://www.benzinga.com/general/market-summary/24/12/42751664/sp-500-ends-2024-23-higher-experts-see-double-digit-growth-for-2025">S&amp;P 500's 22.95% gain</a>. 
This strength has inevitably seeped into telecom-focused ETFs, making them attractive investment avenues. Here are three ETFs that could be a door for investors to ride this wave:
Strong gains in several telecom ETFs speak of the sector's bullish momentum:
<ul>
<li>Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>): Up 10% over the past three months and 31.36% over the past year.</li>
<li>Fidelity MSCI Communication Services Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCOM#NYSE">FCOM</a>): Climbed 9.83% in the past three months and 31.52% over the past year.</li>
<li>iShares U.S. Telecommunications ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IYZ#BATS">IYZ</a>): Gained 6.7% over three months and 15% in a year.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43331404/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
The telecom sector's outlook remains optimistic, considering the positive forecasts in artificial intelligence. Moreover, interest rate cuts throughout 2024, and President Trump&#8217;s push for further rate reductions, could support positive sentiments and hence, industry growth.
Notably, telecom giants AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMSCA#NASDAQ">CMSCA</a>) reported relatively healthy Q4 earnings, reinforcing investor confidence:
<ul>
<li>Comcast<a href="https://www.benzinga.com/25/01/43335926/comcast-q4-earnings-beats-estimates-peacock-subscribers-surge-29-dividend-raised-15-billion-buyback-approved"> exceeded Wall Street's expectations</a>, driven by strong broadband revenues, despite customer losses. Earnings per share (EPS) is at 96 cents adjusted revenue at $31.92 billion; net income was $4.78 billion, up 47% year over year, and adjusted EBITDA growth of 10%.</li>
<li>Verizon's Q4 results reflected healthy growth, with both revenue and earnings <a href="https://www.benzinga.com/news/earnings/25/01/43189382/verizon-q4-earnings-revenue-beat-1-million-mobile-and-broadband-subscriber-adds-business-segment-margin-expands">surpassing estimates</a>. Its EPS was recorded at $1.10 adjusted, revenue at $35.68 billion, and net Income at $5.11 billion, rebounding from a loss a year ago.</li>
<li>AT&amp;T reported <a href="https://www.benzinga.com/25/01/43230968/att-q4-earnings-307k-fiber-adds-projects-mid-teens-broadband-growth-in-2025">strong subscriber growth</a> and operational efficiency gains, with EPS and revenues at $0.54 and $32.3 billion respectively. Net Income of $4.03 billion nearly doubled from a year ago.</li>
<li>T-Mobile&#8217;s stock gained after it reported <a href="https://www.benzinga.com/news/earnings/25/01/43300596/t-mobile-q4-earnings-beats-estimates-adds-1-9-million-postpaid-customers-targets-6-million-new-customers-in-2025">strong fourth-quarter results</a>, surpassing analyst expectations. Its EPS was $2.57, and revenue came in at $21.87 billion.</li>
</ul>
U.S. telecom ETFs remain well-positioned for continued growth thanks to strong corporate earnings and an optimistic industry outlook.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/01/43335143/peo-alphaquest-tidal-launch-etf-with-private-equity-inspired-strategy-thematic-appeal">PEO, AlphaQuest, Tidal Launch ETF With Private Equity-Inspired Strategy, Thematic Appeal</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

ETFs

CMSCA

FCOM

iShares Dow Jones US Telecommunications Sector Index Fund

Telecom ETFs Gain Momentum As Sector Giants AT&T, Verizon, T-Mobile Reinforce Investor Confidence

HC Wainwright &amp; Co. analyst Ed Arce reiterates Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) with a Buy and maintains $13 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $13 Price Target

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) shares are <a href="https://www.benzinga.com/pressreleases/25/01/g43331658/roper-technologies-announces-2024-financial-results">trading higher on Thursday</a>.
The company reported fourth quarter adjusted earnings per share of $4.81, beating the street view of $4.73. Quarterly sales of $1.877 billion outpaced the analyst consensus estimate of $1.829 billion.
Revenue increased by 16%, with a 9% contribution from acquisitions and a 7% increase in organic revenue.
"We grew free cash flow 16% to $2.3 billion, surpassing the $2 billion milestone for the first time in our history,&#8221; said Neil Hunn, Roper Technologies&#8217; President and CEO.
The company exited the quarter with cash and equivalents worth $188.2 million, and net inventories worth $120.8 million.
Also Read: <a href="https://www.benzinga.com/general/travel/25/01/43343648/all-60-passengers-4-crew-members-onboard-american-airlines-jet-feared-dead-after-midair-collision-official-says">64 Killed In American Airlines Midair Collision Near D.C., Worst US Air Disaster Since 2001</a>
&#8220;We deployed $3.6 billion of capital toward high-quality vertical software acquisitions, highlighted by Procare Solutions, a leading early childhood education software company, and Transact Campus, which was successfully combined with our CBORD education &amp; healthcare software business,&#8221; Hunn added.
Roper Technologies' long-term debt (net of current portion) as at quarter end was $6.579 billion, higher than $5.830 billion in the year-ago period.
Outlook: Roper Technologies expects FY25 adjusted earnings per share to be between $19.75 and $20.00, <a href="https://www.benzinga.com/calendars/guidance">slightly below the $20.06 estimate.</a>
For the first quarter, the company anticipates adjusted EPS in the range of $4.70 to $4.74, compared to the $4.84 estimate.
Price Action: ROP shares are trading higher by 6.882% to $580.36 at last check Thursday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details" target="_blank" rel="noreferrer noopener">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

General

Roper Technologies Q4 Earnings Beat, Surpasses $2 Billion Cash Flow Milestone

B of A Securities analyst Robert Ohmes maintains Harley-Davidson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOG#NYSE">HOG</a>) with a Buy and lowers the price target from $40 to $35.

B of A Securities Maintains Buy on Harley-Davidson, Lowers Price Target to $35

Benchmark analyst David Williams reiterates MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Buy and maintains $28 price target.

Benchmark Reiterates Buy on MaxLinear, Maintains $28 Price Target

Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) shares are trading higher Thursday after the company reported better-than-expected financial results <a href="https://www.benzinga.com/pressreleases/25/01/n43331467/quest-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-guidance-fo">for the fourth quarter</a>.
What Happened: Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of $2.23 per share, beating estimates of $2.19 per share. 
Total revenue was up 14.5% year-over-year, while earnings grew 14.7% year-over-year. 
Quest&#8217;s board authorized a 6.7% increase to the company&#8217;s quarterly dividend from 75 cents to 80 cents. The dividend will be payable on April 21 to shareholders of record as of April 7. 
&#8220;In the&nbsp;fourth quarter, we delivered impressive revenue growth of nearly&nbsp;15%, including approximately&nbsp;5%&nbsp;organic growth, while also improving our profitability,&#8221; said&nbsp;Jim Davis, chairman, president and CEO of Quest Diagnostics.
&#8220;For the full year, we drove revenue growth of close to&nbsp;7%, including approximately&nbsp;3%&nbsp;from organic growth. Our team completed eight acquisitions, including LifeLabs in&nbsp;Canada, expanded our advanced diagnostics portfolio, and extended our geographic and market reach with new clinical, consumer and health plan customers.&#8221;
See Also:<a href="https://www.benzinga.com/25/01/43342968/intel-q4-earnings-preview"> Intel Q4 Earnings Preview: CEO Search, PC Demand, Spinoffs On Watch</a>
Outlook: Quest Diagnostics expects full-year 2025 revenue to be in the range of $10.7 billion to $10.85 billion. The company expects earnings to be in the range of $8.34 to $8.59 per share, versus estimates of $8.82 per share. 
&#8220;Our&nbsp;guidance&nbsp;for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024,&#8221; Davis added.
DGX Price Action: <a href="http://benzinga.com/quote/dgx">Quest Diagnostics shares</a> were up 6.01% at $164.78 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Quest Diagnostics Delivers Q4 Earnings Beat: The Details

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $7 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $7 Price Target

B of A Securities analyst Wamsi Mohan maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Buy and raises the price target from $260 to $270.

B of A Securities Maintains Buy on IBM, Raises Price Target to $270

Earlier: Quest Diagnostics Sees FY25 Revenue $10.70B-$10.85B Vs $10.672B Est.

Reported Earlier, Quest Diagnostics Sees FY25 Adj. EPS $9.55-$9.80 Vs $9.75 Estimate

MSFC

MSFT

CORRECTION: Microsoft ticker Is 'MSFT'

WIIM

Microsoft shares are trading lower following Q2 earnings and Q3 outlook.

B of A Securities analyst Alice Xiao maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Underperform and lowers the price target from $40 to $35.

VSCO

B of A Securities Maintains Underperform on Victoria's Secret, Lowers Price Target to $35

HC Wainwright &amp; Co. analyst Heiko Ihle maintains McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) with a Buy and lowers the price target from $19 to $18.

HC Wainwright & Co. Maintains Buy on McEwen Mining, Lowers Price Target to $18

Rogers Communication, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) shares are <a href="https://www.benzinga.com/pressreleases/25/01/g43331914/rogers-communications-reports-fourth-quarter-2024-results-announces-2025-financial-guidance">trading relatively flat on Thursday.</a>
In U.S. dollars, the company reported fourth quarter adjusted earnings per share of $1.04, missing the street view of $1.36. Quarterly sales of $3.92 billion missed the analyst consensus estimate of $5.39 billion.
In Canadian dollars, earnings per share were C$1.02, up 65% year over year, and adjusted earnings per shares were C$1.46.
Wireless service revenue increased by 2% this quarter, primarily as a result of the cumulative impact of growth in mobile phone subscriber base over the past year.
Wireless equipment revenue increased by 9%, primarily as a result of an increase in subscribers purchasing higher-value devices. Cable service revenue was stable this quarter, improving sequentially from the third quarter and from the prior year.
The company declared a <a href="https://www.benzinga.com/pressreleases/25/01/g43331916/rogers-communications-declares-50-cents-per-share-quarterly-dividend">quarterly dividend </a>totaling 50 cents per share on each of its outstanding Class B Non-Voting shares and Class A Voting shares.&nbsp;The declared quarterly dividend will be paid on April 2.
Also Read: <a href="https://www.benzinga.com/general/gaming/25/01/43342224/ryan-cohen-moves-gamestop-shares-to-personal-name-sparking-speculation-on-next-steps">Ryan Cohen Moves 36.8 Million GameStop Shares To Personal Name, Sparking Speculation On Next Steps</a>
Media revenue increased by 10% this quarter, primarily as a result of higher sports- and&nbsp;entertainment-related revenue, but lower than expectations as previously announced.
Consolidated adjusted EBITDA increased 9% and adjusted EBITDA margin increased by 250 basis points, primarily as a result of ongoing productivity and cost efficiencies.
As at December 31, the company had C$4.8 billion of available liquidity (December 31, 2023 &#8211; C$5.9 billion), including C$0.9 billion in cash and equivalents.
&#8220;The fourth quarter caps three straight years of industry-leading results,&#8221; said Tony Staffieri, President and CEO. &#8220;As I look to the year ahead, our 2025 outlook reflects continued growth, strong free cash flow, and investment in our core businesses.&#8221;
Outlook: For FY25, the company sees total service revenue to increase 0% to 3%.
"In 2025, we expect to have the financial flexibility to maintain our network advantages and to continue to return cash to shareholders," the company said.
Price Action: RCI shares are trading higher by 0.97% to $29.03 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In 2024 — Where Do Tesla, Nvidia, GameStop, Trump Media Stocks Rank?</a></li>
</ul>

Rogers Communications Q4 Earnings Miss Expectations, Amid Investments In Core Businesses

Dividends

Earlier: Quest Diagnostics Increased Its Quarterly Dividend From $0.75 To $0.80

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) from Hold to Hold.

SRDX

Needham Reiterates Hold on Surmodicsto Hold

Investors with a lot of money to spend have taken a bullish stance on Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 456 uncommon options trades for Meta Platforms.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 31%, bearish.
Out of all of the special options we uncovered, 52 are puts, for a total amount of $4,705,395, and 404 are calls, for a total amount of $51,327,020.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $1150.0 for Meta Platforms, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Meta Platforms stands at 1890.71, with a total volume reaching 1,328,667.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Meta Platforms, situated within the strike price corridor from $180.0 to $1150.0, throughout the last 30 days.
<h3>Meta Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738257362_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$107.6</td>
<td>$106.05</td>
<td>$106.97</td>
<td>$570.00</td>
<td>$802.9K</td>
<td>334</td>
<td align="right">259</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$221.85</td>
<td>$220.3</td>
<td>$220.3</td>
<td>$870.00</td>
<td>$771.4K</td>
<td>0</td>
<td align="right">48</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$23.35</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$670.00</td>
<td>$368.0K</td>
<td>2.3K</td>
<td align="right">874</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$41.6</td>
<td>$40.95</td>
<td>$41.02</td>
<td>$650.00</td>
<td>$324.5K</td>
<td>4.5K</td>
<td align="right">708</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$42.6</td>
<td>$41.1</td>
<td>$41.97</td>
<td>$650.00</td>
<td>$315.4K</td>
<td>230</td>
<td align="right">328</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
<h3>Meta Platforms's Current Market Status</h3>
<ul>
<li>Trading volume stands at 20,027,013, with META's price up by 2.0%, positioned at $689.99.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Expert Opinions on Meta Platforms</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $789.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Overweight rating on Meta Platforms with a target price of $790. 
&#x2A; In a positive move, an analyst from Benchmark has upgraded their rating to Buy and adjusted the price target to $820. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Meta Platforms, which currently sits at a price target of $775. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on Meta Platforms with a target price of $750. 
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Buy rating on Meta Platforms with a target price of $811. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Meta Platforms with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Meta Platforms's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Riot Platforms.
Looking at options history for Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 54% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $156,400 and 9, calls, for a total amount of $570,075.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $8.5 to $14.0 for Riot Platforms over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Riot Platforms options trades today is 4015.3 with a total volume of 19,924.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Riot Platforms's big money trades within a strike price range of $8.5 to $14.0 over the last 30 days.
<h3>Riot Platforms Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738257356_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.87</td>
<td>$0.86</td>
<td>$0.86</td>
<td>$12.50</td>
<td>$153.0K</td>
<td>784</td>
<td>2.1K</td>
</tr>
<tr>
<td>RIOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$2.15</td>
<td>$1.93</td>
<td>$2.1</td>
<td>$14.00</td>
<td>$126.0K</td>
<td>2.1K</td>
<td>602</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$0.27</td>
<td>$0.25</td>
<td>$0.29</td>
<td>$12.00</td>
<td>$110.6K</td>
<td>14.2K</td>
<td>10.6K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$0.73</td>
<td>$0.72</td>
<td>$0.72</td>
<td>$12.00</td>
<td>$76.0K</td>
<td>3.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>RIOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$10.00</td>
<td>$65.0K</td>
<td>4.8K</td>
<td>220</td>
</tr>
</tbody>
</table>

<h3>About Riot Platforms</h3>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.
Having examined the options trading patterns of Riot Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Riot Platforms's Current Market Status</h3>
<ul>
<li>With a trading volume of 25,745,058, the price of RIOT is up by 3.74%, reaching $11.64.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Riot Platforms</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $16.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham persists with their Buy rating on Riot Platforms, maintaining a target price of $16. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Riot Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

RIOT

What the Options Market Tells Us About Riot Platforms

ArriVent BioPharma: Bringing A Novel Cancer Drug From China

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) and keeping the price target ...

Buy Rating for ArriVent BioPharma Backed by Firmonernib's Efficacy in NSCLC Trials

ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on AVBP stock, giving a Buy rating today. Robert Burns has given his Buy r...

ArriVent BioPharma, Inc. Buy Rating: Strong Financials, Clinical Progress, and Promising Catalysts Support Upside Potential

ArriVent BioPharma, Inc. ( ($AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to its...

ArriVent BioPharma Advances Cancer Therapeutics Pipeline

In a report released on November 26, Yigal Nochomovitz from Citi reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report), with...

Citi Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. ( ($AVBP) ) has provided an announcement. On January 21, 2025, ArriVent BioPharma, Inc. entered into an exclusive license ...

ArriVent BioPharma Expands Oncology Pipeline with New License

H.C. Wainwright raised the firm's price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the shares after the company ...

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report). The associated price ...

ArriVent BioPharma's Strategic Licensing and Partnerships Position It for Growth in ADC Development

ArriVent Biopharma enters license agreement with Lepu Biopharma

AVBP

TKPHF

Press Releases

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Management

ArriVent Appoints Kristine Peterson to its Board of Directors

Health Care

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Comments

ArriVent BioPharma

ニュース

最新ニュース ArriVent BioPharma (NASDAQ:AVBP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル